GET DAILY SIGNALSMoleculin Biotech (MBRX): Q3 2026 Earnings Focus on MIRACLE Trial Updates
Key Takeaways
- Moleculin Biotech is a Phase III clinical-stage drug developer and is expected to report little to no revenue for its fiscal third quarter of 2026.
- Wall Street consensus points to a continued net loss of roughly $0.50 per share for the period, reflecting ongoing investment in its lead cancer program.
- Investors are watching the pivotal MIRACLE trial of Annamycin (also called naxtarubicin) in relapsed or refractory acute myeloid leukemia (AML), rather than the bottom line.
- In the prior quarter, the company posted a GAAP (Generally Accepted Accounting Principles) loss of $1.40 per share, narrower than the $1.55 consensus estimate.
- Cash runway is a central focus: management has indicated funding extends into the first quarter of 2027, with key unblinded efficacy data expected around February 2027.
- For more on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
- You can also discover new trading ideas by exploring Trending AI Robots.
Earnings Context and Why It Matters
For a pre-revenue biotech like Moleculin Biotech, a quarterly earnings report is less about profit and more about two things: how far the lead drug candidate has advanced and whether the company has enough cash to keep running its trials. The company's fiscal calendar follows the standard calendar year, so this report covers the third quarter of 2026, ended September 30, 2026. The pivotal MIRACLE trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) sits at the center of the investment thesis, and any update on enrollment, blinded response rates, or timeline shifts can move the stock far more than the income statement. Investors will also scrutinize the balance sheet, since clinical-stage companies rely on financing to fund research and development. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Analysts expect Moleculin Biotech to report essentially zero revenue for the quarter, consistent with its status as a clinical-stage company with no approved product on the market. Consensus estimates point to a net loss of approximately $0.50 per share, although reported figures can shift with share count and one-time items. For context, in the second quarter of 2026 the company reported a GAAP loss of $1.40 per share, beating the $1.55 consensus estimate, while revenue remained at zero as expected. Rather than revenue or EPS (earnings per share), the metrics investors will likely focus on include research and development expense, the cash balance, and any clinical progress on Annamycin. Guidance and commentary around the MIRACLE trial timeline and funding needs will carry more weight than the headline loss. From what I see, tracking these details helps put the numbers in perspective.
Market Reaction and Investor Sentiment
Sentiment heading into this report centers on the MIRACLE trial, which has shown an early complete remission rate of roughly 36% to 43% compared with a 12% control rate. That signal has supported the bull case, but the company's need for additional financing and its history of wide, reverse-split-adjusted swings in reported per-share figures add volatility. Shares have experienced large price moves around recent updates, reflecting a market that is pricing clinical potential rather than current fundamentals. Key risk factors include trial setbacks, delays in the unblinding timeline, and dilution from future capital raises. Investors will be listening for confirmation of the cash runway and any new clinical data points. I’m watching this closely as the data unfolds.
Forward Outlook and Key Factors to Monitor
Looking ahead, the single most important catalyst is the unblinding of efficacy data from the MIRACLE trial, which management has indicated could arrive around February 2027. This data could shape the regulatory path for Annamycin and, by extension, the company's long-term value.
Cash is the second factor to watch. Management has signaled a runway into the first quarter of 2027, supported by a post-quarter capital raise of roughly $9.3 million. Because the company is pre-revenue, investors should monitor research and development spending and any further financing activity, which can dilute existing shareholders.
Finally, watch for operational milestones such as patient enrollment progress, updates from the MB-107 sarcoma program and the WP1066 portfolio, and any regulatory interactions. Each of these offers incremental signals about whether the clinical pipeline is advancing on schedule. In my view, these milestones will likely drive the next moves more than the quarterly numbers themselves.
Using AI Tools for Biotech Research
I often rely on Tickeron’s AI Screener when evaluating clinical-stage companies like this one. It lets me quickly filter for similar biotechs based on technical patterns, fundamentals, and AI-driven signals, which helps surface comparable ideas without spending hours on manual checks. The tool has become a regular part of my process for staying on top of sectors where clinical progress matters most.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MBRX saw its Stochastic Oscillator peaks and leaves the overbought zone
The Stochastic Oscillator for MBRX moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 39 similar instances where the indicator exited the overbought zone. In 37 of the 39 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MBRX as a result. In 77 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MBRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for MBRX entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MBRX's RSI Oscillator exited the oversold zone, 37 of 45 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for MBRX just turned positive on October 23, 2026. Looking at past instances where MBRX's MACD turned positive, the stock continued to rise in 38 of 41 cases over the following month. The odds of a continued upward trend are 90%.
Following a +5.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where MBRX advanced for three days, in 176 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
MBRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.306) is normal, around the industry mean (3.498). P/E Ratio (0.596) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. MBRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry Biotechnology
Advertisement